{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:07:29Z","timestamp":1794265649906,"version":"4.9.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cytogfr.2024.12.003","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:07:41Z","timestamp":1736035661000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8254-6259","authenticated-orcid":false,"given":"Luka","family":"Hiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijana","family":"Markovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerneja","family":"Farka\u0161 Lain\u0161\u010dak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Mlinari\u010d-Ra\u0161\u010dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2024.12.003_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s42358-020-00151-7","article-title":"Severe COVID-19: what have we learned with the immunopathogenesis?","volume":"60","author":"Bordallo","year":"2020","journal-title":"Adv. Rheumatol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib2","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.3390\/ijms222313009","article-title":"Pathogenesis and treatment of cytokine storm induced by infectious diseases","volume":"22","author":"Tang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","article-title":"Cytokine storm syndrome","volume":"74","author":"Cron","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib4","first-page":"1216","article-title":"Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1","volume":"25","author":"Ferrara","year":"1993","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1182\/blood-2010-01-256099","article-title":"XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/eji.201646686","article-title":"Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire","volume":"47","author":"Ammann","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2018.1.313","article-title":"The rheumatology\/hematology interface: CAPS and MAS diagnosis and management","volume":"2018","author":"Gansner","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib8","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib9","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib10","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib12","unstructured":"COVID-19 cases|WHO COVID-19 dashboard, Datadot, n.d., \u3008https:\/\/data.who.int\/dashboards\/covid19\/cases\u3009 (Accessed 26 January 2024)."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib13","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3390\/v15101994","article-title":"Clinical severity of SARS-CoV-2 variants during COVID-19 vaccination: a systematic review and meta-analysis","volume":"15","author":"Yuan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib14","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib15","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis","volume":"81","author":"Zheng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"van der Made","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib17","article-title":"Risk factors for severe COVID-19 in children: a systematic review and meta-analysis","volume":"37","author":"Choi","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209610","article-title":"The protein expression profile of ACE2 in human tissues","volume":"16","author":"Hikmet","year":"2020","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib19","doi-asserted-by":"crossref","unstructured":"D. Castanares-Zapatero, P. Chalon, L. Kohn, M. Dauvrin, J. Detollenaere, C. Maertens de Noordhout, C. Primus-de Jong, I. Cleemput, K. Van den Heede, Pathophysiology and mechanism of long COVID: a comprehensive review, Ann. Med., 54, n.d, pp. 1473\u201387, doi:10.1080\/07853890.2022.2076901.","DOI":"10.1080\/07853890.2022.2076901"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccm.2018.07.005","article-title":"Influenza and viral pneumonia","volume":"39","author":"Cavallazzi","year":"2018","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18991-2","article-title":"SepsEast Registry indicates high mortality associated with COVID-19 caused acute respiratory failure in Central-Eastern European intensive care units","volume":"12","author":"Benes","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/ijms18020388","article-title":"Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy","volume":"18","author":"Lee","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/ijms18010064","article-title":"Current Concepts of ARDS: a narrative review","volume":"18","author":"Umbrello","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12985-021-01588-y","article-title":"Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction","volume":"18","author":"Wang","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib25","article-title":"Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib26","doi-asserted-by":"crossref","DOI":"10.2174\/1567205019666220908084559","article-title":"Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19","author":"Tsagkaris","year":"2022","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12985-023-02116-w","article-title":"Neutrophils in COVID-19: recent insights and advances","volume":"20","author":"Li","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.12669\/pjms.37.7.4085","article-title":"Lymphopenia: a useful predictor of COVID-19 disease severity and mortality","volume":"37","author":"Toori","year":"2021","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41598-020-79431-7","article-title":"Neutrophil-to-lymphocyte ratio and mortality in the United States general population","volume":"11","author":"Song","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.706902","article-title":"Th2\/Th1 cytokine imbalance is associated with higher COVID-19 risk mortality","volume":"12","author":"Pavel","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: from cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13131","article-title":"COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: potential targets and challenges","volume":"95","author":"Pourgholaminejad","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib35","first-page":"1","article-title":"Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID\u00ad19","volume":"5","author":"Abd El-Aziz","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1381612826666200115092015","article-title":"Emerging role of angiotensin AT2 receptor in anti-inflammation: an update","volume":"26","author":"Patel","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B978-0-12-801364-9.00025-0","article-title":"ACE2 cell biology, regulation, and physiological functions","author":"Turner","year":"2015","journal-title":"Prot. Arm. Renin Angiotensin Syst. RAS"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-022-03842-5","article-title":"Angiotensin-(1\u20137) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-\u03baB and MAPK pathways","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117905","article-title":"Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications","volume":"256","author":"Banu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41440-023-01460-2","article-title":"The role of SARS-CoV-2-mediated NF-\u03baB activation in COVID-19 patients","volume":"47","author":"Zhou","year":"2024","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib41","series-title":"Mol. Biol. Cell","article-title":"Innate immunity","author":"Alberts","year":"2002"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib42","series-title":"Immunobiol. Immune Syst. Health Dis.","article-title":"The course of the adaptive response to infection","author":"Charles","year":"2001"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","article-title":"Serum IgA, IgM, and IgG responses in COVID-19","volume":"17","author":"Ma","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1119564","article-title":"A four-part guide to lung immunology: invasion, inflammation, immunity, and intervention","volume":"14","author":"Gopallawa","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"Beutler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib48","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1128\/JVI.01918-14","article-title":"MAVS coordination of antiviral innate immunity","volume":"89","author":"Vazquez","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib49","article-title":"Toll-like receptors (TLRs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility","volume":"2021","author":"Sameer","year":"2021","journal-title":"BioMed\u00a0Res. Int."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9914854","article-title":"Toll-like receptors: general molecular and structural biology","volume":"2021","author":"Behzadi","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib51","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021107826","article-title":"SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation","volume":"40","author":"Thorne","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib52","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3389\/fimmu.2019.01586","article-title":"Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5","volume":"10","author":"Brisse","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/17534259211051364","article-title":"TLRs in COVID-19: how they drive immunopathology and the rationale for modulation","volume":"27","author":"Mabrey","year":"2021","journal-title":"Innate Immun."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136947","article-title":"Roles of TLR\/MyD88\/MAPK\/NF-\u03baB signaling pathways in the regulation of phagocytosis and proinflammatory cytokine expression in response to E. faecalis infection","volume":"10","author":"Zou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib55","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","article-title":"30 years of NF-\u03baB: a blossoming of relevance to human pathobiology","volume":"168","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib58","article-title":"Molecular mechanisms involved in pathogenicity of SARS-CoV-2: immune evasion and implications for therapeutic strategies","volume":"153","author":"Latifi-Pupovci","year":"2022","journal-title":"Biomed.\u00a0Pharmacother."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104960","article-title":"Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease","volume":"299","author":"Samuel","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib60","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00313","article-title":"The impact of the interferon\/TNF-related apoptosis-inducing ligand signaling axis on disease progression in respiratory viral infection and beyond","volume":"8","author":"Peteranderl","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib62","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I interferon drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing","author":"Simmons","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib63","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fimmu.2019.00778","article-title":"Sources of type I interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver\u2019s seat","volume":"10","author":"Ali","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib64","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888897","article-title":"Dysregulated interferon response and immune hyperactivation in severe COVID-19: targeting STATs as a novel therapeutic strategy","volume":"13","author":"Eskandarian Boroujeni","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib68","doi-asserted-by":"crossref","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Beh\u00e7et\u2019s disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261428","article-title":"Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: a complex relationship","volume":"17","author":"Dananch\u00e9","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib71","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s43440-022-00394-9","article-title":"The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic","volume":"74","author":"Majchrzak","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583373","article-title":"The inflammasome in times of COVID-19","volume":"11","author":"de Rivero Vaccari","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.chom.2022.12.005","article-title":"An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2","volume":"31","author":"Barnett","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib74","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib77","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/j.1582-4934.2010.01127.x","article-title":"Endogenous toll-like receptor ligands and their biological significance","volume":"14","author":"Yu","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib78","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/jmv.25987","article-title":"In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs","volume":"92","author":"Choudhury","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib79","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-022-00922-w","article-title":"How location and cellular signaling combine to activate the NLRP3 inflammasome","volume":"19","author":"Akbal","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fmicb.2019.00050","article-title":"Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virol.2022.01.003","article-title":"SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway","volume":"568","author":"Xu","year":"2022","journal-title":"Virology"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib82","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3389\/fimmu.2020.01580","article-title":"Severe COVID-19: NLRP3 inflammasome dysregulated","volume":"11","author":"van den Berg","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib83","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.molcel.2022.04.033","article-title":"Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells","volume":"82","author":"Plan\u00e8s","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib84","doi-asserted-by":"crossref","unstructured":"L. de Almeida A.L.N. da Silva T.S. Rodrigues S. Oliveira A.Y. Ishimoto A.A. Seribelli A. Becerra W.A. Andrade M.A. Ataide C.C.S. Caetano K.S.G. de S\u00e1 N. Pelisson R.B. Martins J. de Paula Souza E. Arruda S.S. Batah R. Castro F.G. Frantz F.Q. Cunha T.M. Cunha A.T. Fabro L.D. Cunha P. Louzada-Junior R.D.R. de Oliveira D.S. Zamboni Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection Sci. Adv. 8 eabo5400 doi:\u00a010.1126\/sciadv.abo5400.","DOI":"10.1126\/sciadv.abo5400"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib85","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3389\/fimmu.2020.01840","article-title":"Human autoinflammatory diseases mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-inflammasome dysregulation updates on diagnosis, treatment, and the respective roles of IL-1 and IL-18","volume":"11","author":"Alehashemi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658896","article-title":"Cytokine overproduction and immune system dysregulation in alloHSCT and COVID-19 patients","volume":"12","author":"Lange","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19\u2014immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper","volume":"11","author":"Bhaskar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1\u03b1, IL-33 and S100 proteins: dual-function alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib91","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/biom12071005","article-title":"Activation and pharmacological regulation of inflammasomes","volume":"12","author":"Chen","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib93","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41467-021-22449-w","article-title":"IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals","volume":"12","author":"Stanczak","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib94","first-page":"1","article-title":"Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib95","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib96","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.72.5.847","article-title":"Multiple control of interleukin-8 gene expression","volume":"72","author":"Hoffmann","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108516","article-title":"Neutrophil extracellular traps (NETs) and Covid-19: a new frontiers for therapeutic modality","volume":"104","author":"Al-Kuraishy","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib99","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib101","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: biology, signaling and strategies of blockade","volume":"26","author":"Schaper","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib102","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1916","article-title":"Interleukin-6: discovery of a pleiotropic cytokine","volume":"8","author":"Kishimoto","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib103","doi-asserted-by":"crossref","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib104","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome","volume":"56","author":"Chen","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib105","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1631\/jzus.2005.B1045","article-title":"Acute phase reaction and acute phase proteins","volume":"6","author":"Gruys","year":"2005","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2022.100110","article-title":"The mechanistic basis linking cytokine storm to thrombosis in COVID-19","volume":"8","author":"Wolf","year":"2022","journal-title":"Thromb. Update"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib108","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3389\/fimmu.2019.00680","article-title":"The pivotal role of regulatory T cells in the regulation of innate immune cells","volume":"10","author":"Okeke","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib109","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 responses: what are they?","volume":"321","author":"Berger","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib111","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/B978-012374410-4.00591-4","article-title":"Immune response to viruses: antibody-mediated immunity","author":"Neurath","year":"2008","journal-title":"Encycl. Virol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib113","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","article-title":"The role of interleukin 6 during viral infections","volume":"10","author":"Velazquez-Salinas","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib114","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","author":"Rose-John","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib115","first-page":"108","article-title":"Cytokines and cytokine receptors","volume":"9","author":"O\u2019Shea","year":"2013"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","article-title":"Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling","volume":"17","author":"Reeh","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib117","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s12668-022-00997-9","article-title":"Application of monoclonal antibody drugs in treatment of COVID-19: a review","volume":"12","author":"Kirillova","year":"2022","journal-title":"BioNanoScience"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.592727","article-title":"Increased serum levels of soluble TNF-\u03b1 receptor is associated with ICU mortality in COVID-19 patients","volume":"12","author":"Mortaz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib120","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/eji.200425097","article-title":"Activated T killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-\u03b1","volume":"34","author":"Shinbori","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib121","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib122","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12964-020-00564-3","article-title":"The TNF\/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect","volume":"18","author":"Naserian","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib123","article-title":"Targeting TNF-\u03b1 for COVID-19: recent advanced and controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib125","first-page":"1","article-title":"The role of cell death in SARS-CoV-2 infection","volume":"8","author":"Yuan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.725473","article-title":"The TNF-\u03b1\/TNFR2 pathway: targeting a brake to release the anti-tumor immune response","volume":"9","author":"Moatti","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120063","article-title":"The role of TNFR2 +\u2009Tregs in COVID-19: an overview and a potential therapeutic strategy","volume":"286","author":"Ahmad","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","article-title":"TNF-\u03b1 signalling and inflammation: interactions between old acquaintances","volume":"62","author":"Zelov\u00e1","year":"2013","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib129","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2008-06-162008","article-title":"Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children","volume":"112","author":"Atkinson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib130","doi-asserted-by":"crossref","unstructured":"I. Popescu M.E. Snyder C.J. Iasella S.J. Hannan R. Koshy R. Burke A. Das M.J. Brown E.J. Lyons S.C. Lieber X. Chen J.C. Sembrat P. Bhatt E. Deng X. An K. Linstrum G. Kitsios I. Konstantinidis M. Saul D.J. Kass J.K. Alder B.B. Chen E.A. Lendermon S. Kilaru B. Johnson J.M. Pilewski J.E. Kiss A.H. Wells A. Morris B.J. McVerry D.K. McMahon D.J. Triulzi K. Chen P.G. Sanchez J.F. McDyer CD4+ T-cell dysfunction in severe COVID-19 disease is tumor necrosis factor-\u03b1\/tumor necrosis factor receptor 1\u2013dependent Am. J. Respir. Crit. Care Med. 205 1403 1418 doi:\u00a010.1164\/rccm.202111-2493OC.","DOI":"10.1164\/rccm.202111-2493OC"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib131","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib132","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.13464","article-title":"NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion\u2014the differences and similarities","volume":"166","author":"Roe","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109177","article-title":"Exhaustion and over-activation of immune cells in COVID-19: challenges and therapeutic opportunities","volume":"245","author":"Alahdal","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104196","article-title":"TNF contributes to T-cell exhaustion in chronic L. mexicana infections of mice through PD-L1 up-regulation","volume":"358","author":"Gonz\u00e1lez-Tafoya","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","article-title":"TNF-\u03b1-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer","volume":"17","author":"Zheng","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib136","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor necrosis factor \u03b1 and regulatory T cells in oncoimmunology","volume":"9","author":"Salomon","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib137","unstructured":"N.C. Nicolaides, G. Chrousos, T. Kino, Glucocorticoid Receptor, in: K.R. Feingold, B. Anawalt, M.R. Blackman, A. Boyce, G. Chrousos, E. Corpas, W.W. de Herder, K. Dhatariya, K. Dungan, J. Hofland, S. Kalra, G. Kaltsas, N. Kapoor, C. Koch, P. Kopp, M. Korbonits, C.S. Kovacs, W. Kuohung, B. Laferr\u00e8re, M. Levy, E.A. McGee, R. McLachlan, M. New, J. Purnell, R. Sahay, A.S. Shah, F. Singer, M.A. Sperling, C.A. Stratakis, D.L. Trence, D.P. Wilson (Eds.), Endotext, MDText.com, Inc., South Dartmouth (MA), 2000. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279171\/\u3009 (Accessed 10 October 2024)."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib138","article-title":"Tackling the cytokine storm in COVID-19, challenges and hopes","volume":"257","author":"Sm","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib139","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.3390\/ijms23095283","article-title":"The role of nuclear factor kappa B (NF-\u03baB) in development and treatment of COVID-19: review","volume":"23","author":"Gudowska-Sawczuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib141","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17476348.2023.2177155","article-title":"Safety and efficacy of glucocorticoids in the treatment of COVID-19: a meta-analysis of randomized control trials","volume":"17","author":"Qiao","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib143","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12879-023-08874-w","article-title":"Efficacy and safety of glucocorticoids use in patients with COVID-19: a systematic review and network meta\u2011analysis","volume":"23","author":"He","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib144","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2386","article-title":"Effect of corticosteroid therapy on mortality in COVID-19 patients\u2014a systematic review and meta-analysis","volume":"32","author":"Patel","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib145","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib146","unstructured":"Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19, FDA, 2020. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19\u3009 (Accessed 25 January\u00a02024)."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib147","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","author":"RECOVERY Collaborative Group","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib148","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1293331","article-title":"Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib150","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib151","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40121-021-00545-0","article-title":"efficacy and safety of immunomodulators in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"11","author":"Ngamprasertchai","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib152","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib153","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with covid-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib154","first-page":"243","article-title":"The efficacy and safety of monoclonal antibody treatments against COVID-19: a systematic review and meta-analysis of randomized clinical trials","volume":"55","author":"Wafa","year":"2023","journal-title":"Acta Med. Indones."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14740338.2021.1946513","article-title":"Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database","volume":"20","author":"Charan","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib156","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2022.11.017","article-title":"Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness","volume":"126","author":"Langer-Gould","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib158","doi-asserted-by":"crossref","unstructured":"S.-H. Lan C.-K. Hsu S.-P. Chang L.-C. Lu C.-C. Lai Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials Ann. Med. 55 2208872 doi:\u00a010.1080\/07853890.2023.2208872.","DOI":"10.1080\/07853890.2023.2208872"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib159","article-title":"Interleukin-1 blocking agents for treating COVID-19","volume":"2022","author":"Davidson","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40001-023-01072-z","article-title":"Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"28","author":"Dahms","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24434","article-title":"Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: a meta-analysis","volume":"36","author":"Naveed","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107961","article-title":"Evaluation of adalimumab effects in managing severe cases of COVID-19: a randomized controlled trial","volume":"99","author":"Fakharian","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib163","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.16717","article-title":"Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments","volume":"55","author":"Kokkotis","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib164","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O\u2019Halloran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106190","article-title":"Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis","volume":"89","author":"Jiang","year":"2024","journal-title":"J. Infect."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib166","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: milestones, lessons, and prospects","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib167","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"2022","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib168","doi-asserted-by":"crossref","DOI":"10.34172\/jrhs.2024.161","article-title":"COVID-19 vaccine effectiveness of booster doses against delta and omicron variants over follow-up times using longitudinal meta-analysis","volume":"24","author":"Mostafavi","year":"2024","journal-title":"J. Res. Health Sci."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib169","article-title":"Feasibility and effectiveness of vaccines for COVID-19: an umbrella review","volume":"13","author":"SeyedAlinaghi","year":"2025","journal-title":"Arch. Acad. Emerg. Med."},{"key":"10.1016\/j.cytogfr.2024.12.003_bib170","doi-asserted-by":"crossref","unstructured":"Lives saved by COVID-19 vaccines, J. Paediatr. Child Health, vol. 58, 2022, pp. 2129\u20132129, doi: 10.1111\/jpc.16213.","DOI":"10.1111\/jpc.16213"},{"key":"10.1016\/j.cytogfr.2024.12.003_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105768","article-title":"Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: systematic review and network meta-analysis","volume":"221","author":"Zur","year":"2024","journal-title":"Antivir. Res."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:20:56Z","timestamp":1741785656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610124001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":171,"alternative-id":["S1359610124001047"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.12.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}